Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
Volume
197.55 K
Value Traded
-
Short % Float
0.05%
Days to Cover
1.0
+5.29%Week
+3.06%1 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.44 B
EPS (TTM)
-0.15
P/E Ratio
-
Ent. Value
1.44 B
Total Shares
45.54 M
Float Shares
44.96 M
Insiders
1.27%
Institutions
21.30%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
KRSA Catalyst Timeline
Dated clinical, regulatory and corporate events for Korsana Biosciences, Inc.
Past FDA Catalysts and PDUFA Decisions
How KRSA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every KRSA program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| CHICKO RHONDA M.Officer (Chief Financial Officer) | Option | 25,000 25,018 held | $2.36 | 08/14/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in KRSA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in KRSA for Q2 2026. | ||||
Ownership Trends
KRSA Short Interest
Shares sold short, counted twice a month.
0.05%
Short % of Float
of tradable shares sold short
23.8K
Shares Sold Short
+106.1% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
97.8K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How KRSA ranks across every disease it competes in
Competitive Position is a premium feature
See how KRSA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialKRSA News
-KRSA
Nov 2, 2026▲ +5%today
Korsana Biosciences to Participate in Upcoming Investor Conferences
Korsana Biosciences announced its participation in several upcoming investor conferences, including the Guggenheim and Stifel Healthcare Conferences. The events will feature fireside chats and presentations scheduled from November 9 to November 17, 2026. The company aims to advance its lead program, KRSA-028, targeting Alzheimer's disease.
Read more →-KRSA
Sep 8, 2026Korsana Biosciences Completes Closing of Merger with Cyclerion Therapeutics and Previously Announced Private Placement of $380 Million
Korsana Biosciences has successfully completed its merger with Cyclerion Therapeutics, alongside a private placement that raised $380 million. This merger is expected to strengthen Korsana's financial position and advance its lead program, KRSA-028, toward clinical trials. Phase 1 data from healthy volunteers is anticipated by mid-2027, with interim data in Alzheimer's patients expected by late 2027 or early 2028.
Read more →-KRSA
Aug 3, 2026Korsana Biosciences Strengthens Leadership with Executive and Board Appointments to Support Next Phase of Growth
Korsana Biosciences has appointed Matthew Leoni, M.D., as Chief Medical Officer and Gan Wei, Ph.D., as Chief Technical Officer, alongside Heidi Henson to its Board of Directors. These appointments aim to bolster Korsana's leadership as it advances its Alzheimer's treatment, KRSA-028, towards clinical development. The company also anticipates a merger with Cyclerion Therapeutics in Q3 2026.
Read more →-KRSA
Mar 16, 2026Korsana Biosciences Appoints Mark Vignola, Ph.D., as Chief Financial Officer
Korsana Biosciences has appointed Mark Vignola, Ph.D., as Chief Financial Officer. With over 15 years of experience in corporate finance within the biotech sector, Dr. Vignola aims to support Korsana's mission of developing innovative therapies for neurodegenerative diseases. His previous roles include CFO positions at Terns Pharmaceuticals and Applied Therapeutics, where he successfully led financing efforts.
Read more →-KRSA
Mar 12, 2026Korsana Biosciences to Present at the Stifel 2026 Virtual CNS Forum
Korsana Biosciences will present at the Stifel 2026 Virtual CNS Forum on March 17, 2026. CEO Jonathan Violin will discuss the company's novel therapies aimed at neurodegenerative diseases. Korsana's THETA platform is designed to improve drug delivery to the brain, with KRSA-028 targeting Alzheimer's disease. A live webcast will be available on their website.
Read more →-KRSA
Feb 18, 2026Korsana Biosciences Emerges from Stealth with $175 Millon in Funding to Advance Potential Best-in-Class Therapeutics for Neurodegenerative Diseases
Korsana Biosciences has emerged from stealth with $175 million in funding to develop KRSA-028, a next-generation monoclonal antibody targeting amyloid beta for Alzheimer's disease. The funding will support the company's mission to create best-in-class therapeutics for neurodegenerative diseases, leveraging its proprietary THETA™ platform. Korsana is led by CEO Jonathan Violin and aims to address the growing need for effective Alzheimer's treatments.
Read more →About Korsana Biosciences, Inc.
Headquarters301 BINNEY STREET, CAMBRIDGE, MA, 02142
BIOPHARMAWATCH ELITE PLUS
Trade the next KRSA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime